DNMT1 and bladder transitional cell carcinoma: While BLCA patients are routinely treated with intravesical BCG, intravesical chemotherapy, or cisplatin-based chemotherapy, depending on the stage of the disease, no DNMT-targeted strategy is currently used as a standard treatment approach.